Suppr超能文献

从主治医生的视角进行耳毒性监测:来自肺病学和医学肿瘤学的观点。

Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.

作者信息

Garinis Angela C, Cornell Alexandra, Allada Gopal, Fennelly Kevin P, Maggiore Ronald J, Konrad-Martin Dawn

机构信息

a Department of Otolaryngology - Head and Neck Surgery , Oregon Health & Science University , Portland , OR , USA.

b VA Portland Health Care System , VA RR&D Center of Excellence, National Center for Rehabilitative Auditory Research , Portland , OR , USA.

出版信息

Int J Audiol. 2018 Sep;57(sup4):S19-S24. doi: 10.1080/14992027.2017.1381769. Epub 2017 Oct 5.

Abstract

OBJECTIVES

Integrating audiological management into the care pathways of clinical specialties that prescribe ototoxic medications for essential, often life-preserving medical care that is critical for early hearing loss identification and remediation. Research shows that successful implementation of a new health service or intervention requires alignment of goals among provider groups, institutional leadership and patients. Thoughtful consideration of the physician's viewpoints about ototoxicity and its implications for treatment planning is, therefore, important for the implementation and enduring success of an ototoxicity monitoring programme (OMP).

DESIGN

This discussion paper uses qualitative methods to explore the perspectives of four physicians on OMP provision in their patient populations.

STUDY SAMPLE

Three pulmonologists and one oncologist completed the written survey or survey-based interview described in this report.

RESULTS

Each physician indicated that (i) ototoxicity is a potential problem for their patients; (ii) monitoring hearing is important to ensure good quality of life among their patients and (iii) treatment modification would be considered if an alternative treatment option were available. The physicians differed in their approaches to ototoxicity monitoring, from routine referrals to audiology, to relying on patient self-referral.

CONCLUSION

Physician provider input is needed to optimise monitoring schedules and OMP care coordination with audiology.

摘要

目标

将听力学管理纳入临床专科的护理路径,这些专科会开具耳毒性药物用于必要的、往往能挽救生命的医疗护理,这对于早期听力损失的识别和补救至关重要。研究表明,成功实施一项新的健康服务或干预措施需要提供者群体、机构领导层和患者之间目标一致。因此,认真考虑医生对耳毒性及其对治疗计划影响的观点,对于耳毒性监测计划(OMP)的实施和持久成功至关重要。

设计

本讨论文件采用定性方法,探讨四位医生对其患者群体中OMP提供情况的看法。

研究样本

三位肺科医生和一位肿瘤学家完成了本报告中描述的书面调查或基于调查的访谈。

结果

每位医生都表示:(i)耳毒性对其患者来说是一个潜在问题;(ii)监测听力对于确保患者的良好生活质量很重要;(iii)如果有替代治疗方案,会考虑调整治疗。医生们在耳毒性监测方法上存在差异,从常规转诊到听力学,再到依靠患者自我转诊。

结论

需要医生提供者的投入,以优化监测时间表以及OMP与听力学的护理协调。

相似文献

1
Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.
Int J Audiol. 2018 Sep;57(sup4):S19-S24. doi: 10.1080/14992027.2017.1381769. Epub 2017 Oct 5.
3
Current practice of ototoxicity management across the United Kingdom (UK).
Int J Audiol. 2018 Sep;57(sup4):S76-S88. doi: 10.1080/14992027.2018.1460495. Epub 2018 Apr 20.
4
Ototoxicity monitoring in children treated with platinum chemotherapy.
Int J Audiol. 2018 Sep;57(sup4):S34-S40. doi: 10.1080/14992027.2017.1355570. Epub 2017 Jul 24.
5
Clinical trials, ototoxicity grading scales and the audiologist's role in therapeutic decision making.
Int J Audiol. 2018 Sep;57(sup4):S89-S98. doi: 10.1080/14992027.2017.1417644. Epub 2017 Dec 23.
7
Monitoring neonates for ototoxicity.
Int J Audiol. 2018 Sep;57(sup4):S41-S48. doi: 10.1080/14992027.2017.1339130. Epub 2017 Jun 22.
8
Using tablet-based technology to deliver time-efficient ototoxicity monitoring.
Int J Audiol. 2018 Sep;57(sup4):S25-S33. doi: 10.1080/14992027.2017.1370138. Epub 2017 Sep 12.
9
Perspectives and practices of ototoxicity monitoring.
S Afr J Commun Disord. 2020 May 19;67(1):e1-e10. doi: 10.4102/sajcd.v67i1.685.
10
Development and validation of a cisplatin dose-ototoxicity model.
J Am Acad Audiol. 2012 Jul-Aug;23(7):510-21. doi: 10.3766/jaaa.23.7.3.

引用本文的文献

1
Mobile Audiometry for Use in Ototoxicity Monitoring Programs: A Scoping Review.
J Audiol Otol. 2025 Jul;29(3):166-180. doi: 10.7874/jao.2024.00815. Epub 2025 Jul 18.
2
Ototoxicity Monitoring: The Evolution of a Protocol for Head and Neck Cancer Patients.
OTO Open. 2025 Apr 7;9(2):e70070. doi: 10.1002/oto2.70070. eCollection 2025 Apr-Jun.
4
Oncologists' views on ototoxicity monitoring in head and neck cancer patients: A South Indian qualitative study.
PLoS One. 2025 Jan 3;20(1):e0312847. doi: 10.1371/journal.pone.0312847. eCollection 2025.
6
Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.
J Cancer Surviv. 2024 Apr 17. doi: 10.1007/s11764-024-01586-3.
8
Ototoxicity monitoring in South African cancer facilities: A national survey.
S Afr J Commun Disord. 2022 Jan 19;69(1):e1-e10. doi: 10.4102/sajcd.v69i1.846.
9
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
Am J Audiol. 2021 Oct 11;30(3S):800-809. doi: 10.1044/2021_AJA-21-00031. Epub 2021 Sep 22.
10
The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study.
J Cancer Surviv. 2022 Oct;16(5):976-987. doi: 10.1007/s11764-021-01089-5. Epub 2021 Aug 16.

本文引用的文献

2
The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
J Cyst Fibros. 2017 May;16(3):401-409. doi: 10.1016/j.jcf.2017.01.006. Epub 2017 Feb 24.
3
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.
Head Neck. 2016 Apr;38 Suppl 1:E2151-8. doi: 10.1002/hed.24026. Epub 2015 Jul 14.
4
Medications and monitoring in nontuberculous mycobacteria infections.
Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.
5
A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Respir Care. 2014 Sep;59(9):1353-9. doi: 10.4187/respcare.02980. Epub 2014 Apr 29.
7
Platinum-based agents for individualized cancer treatment.
Curr Mol Med. 2013 Dec;13(10):1603-12. doi: 10.2174/1566524013666131111125515.
8
Platinum-based compounds for the treatment of metastatic breast cancer.
Chemotherapy. 2011;57(6):468-87. doi: 10.1159/000334093. Epub 2012 Jan 10.
10
Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
Pediatr Infect Dis J. 2006 Mar;25(3):276-8. doi: 10.1097/01.inf.0000202126.44544.41.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验